Regulatory T Cells in Allogeneic Transplantation

同种异体移植中的调节性 T 细胞

基本信息

  • 批准号:
    7855234
  • 负责人:
  • 金额:
    $ 118.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-30 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cellular therapy has enormous potential for the treatment of a broad range of diseases. Currently, hematopoietic cell transplantation (HCT) serves as the major example of the use of cell based therapeutics currently practiced in clinical medicine. Many advances in the understanding of the role of specific cell populations performed in animal models demonstrate the potential for the extension of this mode of therapy into a number of other important areas. However, key limitations including the availability of suitably matched donors and the risk of graft vs. host disease (GVHD) limit the effectiveness and application of this potential treatment strategy. In this GO TRIP stage I proposal we will attempt to translate novel insights from our laboratory and others that have demonstrated the potential functional role of key cell populations that could have a major impact in the success and application of cellular therapeutics in the clinic. In the proposal we will pursue a clinical trial of CD4+CD25+FoxP3+ regulatory T cells (Treg) in HCT and to attempt to develop at least one other cellular therapeutic with strong preclinical data. Central to the successful application of these treatment strategies is the effective isolation of sometimes rare populations of cells using high speed cell sorting on a clinical scale. The proposal seeks support to implement a clinical trial of Treg where development including scale-up, validation and IND submission has already been completed. The trial will be pursued in patients undergoing haploidentical transplantation due to the unmet clinical need and the view that this clinical setting will allow for rapid assessment of Treg function. Further, the proposal will establish a Translation Team to evaluate three other potential cellular populations including purified hematopoietic stem cells, common lymphoid progenitor cells and effector memory CD8+ T cells which have all been studied by investigators within the Program with the goal of bringing one or possibly two of these proposals forward to development, validation and IND submission. The proposal will advance critical science, develop novel technology and provide critical jobs for the important development and implementation of novel cellular therapeutics. PUBLIC HEALTH RELEVANCE: A Clinical Trials Project Manager will be hired to oversee the operations of a multicenter, Phase III clinical trial. For elderly patients with acute myeloid leukemia, this trial is attempting to determine if allogeneic hematopoietic cell transplantation can improve the poor prognoses typically seen in this patient population. Preliminary studies, so far, have demonstrated favorable results with this specific type of transplant.
描述(由申请人提供):细胞疗法具有治疗广泛疾病的巨大潜力。目前,造血细胞移植(HCT)作为目前在临床医学中实践的基于细胞的治疗剂的使用的主要实例。在动物模型中进行的特定细胞群的作用的理解的许多进展证明了这种治疗模式扩展到许多其他重要领域的潜力。然而,关键的限制,包括适当匹配的供体的可用性和移植物抗宿主病(GVHD)的风险限制了这种潜在的治疗策略的有效性和应用。在这个GO TRIP第一阶段的提案中,我们将尝试翻译我们实验室和其他人的新见解,这些见解已经证明了关键细胞群的潜在功能作用,这些细胞群可能对细胞疗法在临床中的成功和应用产生重大影响。在该提案中,我们将继续进行HCT中CD4+CD25+FoxP3+调节性T细胞(Treg)的临床试验,并尝试开发至少一种具有强大临床前数据的其他细胞治疗药物。成功应用这些治疗策略的核心是在临床规模上使用高速细胞分选有效分离有时罕见的细胞群。该提案寻求支持实施Treg的临床试验,其中包括规模扩大,验证和IND提交的开发已经完成。由于临床需求未得到满足,并且认为该临床环境将允许快速评估Treg功能,因此将在接受单倍体相合移植的患者中进行试验。此外,该提案将建立一个翻译团队,以评估其他三种潜在的细胞群,包括纯化的造血干细胞、常见的淋巴祖细胞和效应记忆CD8+ T细胞,这些细胞群都已由该项目内的研究者进行了研究,目的是将其中一种或两种提案用于开发、验证和IND提交。该提案将推进关键科学,开发新技术,并为新细胞疗法的重要开发和实施提供关键工作。 公共卫生相关性:将聘请一名临床试验项目经理监督多中心III期临床试验的运作。对于老年急性髓性白血病患者,该试验试图确定异基因造血细胞移植是否可以改善该患者人群中常见的不良预后。到目前为止,初步研究已经证明了这种特定类型移植的良好结果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert S Negrin其他文献

Treatment of donors with liposomal alpha-galactosylceramide results in the in vivo expansion of invariant natural killer T cells and reduced incidence of acute graft versus host disease
用脂质体 α-半乳糖神经酰胺治疗供体可导致不变自然杀伤 T 细胞体内扩增,并降低急性移植物抗宿主病的发生率
  • DOI:
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Toshihito Hirai;Federico Simonetta;Kristina Mass-Bauer;Jeanette Baker;Mustafa Tukoz;Maite Alvarez;Melissa Mavers;Robert S Negrin
  • 通讯作者:
    Robert S Negrin

Robert S Negrin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert S Negrin', 18)}}的其他基金

Regulatory T cells in allogeneic transplantation
同种异体移植中的调节性T细胞
  • 批准号:
    9065603
  • 财政年份:
    2012
  • 资助金额:
    $ 118.43万
  • 项目类别:
Regulatory T cells in allogeneic transplantation
同种异体移植中的调节性T细胞
  • 批准号:
    8903997
  • 财政年份:
    2012
  • 资助金额:
    $ 118.43万
  • 项目类别:
Regulatory T cells in allogeneic transplantation
同种异体移植中的调节性T细胞
  • 批准号:
    8534275
  • 财政年份:
    2012
  • 资助金额:
    $ 118.43万
  • 项目类别:
Regulatory T cells in allogeneic transplantation
同种异体移植中的调节性T细胞
  • 批准号:
    8701379
  • 财政年份:
    2012
  • 资助金额:
    $ 118.43万
  • 项目类别:
Regulatory T cells in allogeneic transplantation
同种异体移植中的调节性T细胞
  • 批准号:
    8343992
  • 财政年份:
    2012
  • 资助金额:
    $ 118.43万
  • 项目类别:
Allografting for Lukemia
白血病同种异体移植
  • 批准号:
    8260361
  • 财政年份:
    2011
  • 资助金额:
    $ 118.43万
  • 项目类别:
Control of GVHD with Retained GVT
通过保留 GVT 控制 GVHD
  • 批准号:
    8260364
  • 财政年份:
    2011
  • 资助金额:
    $ 118.43万
  • 项目类别:
Hematopoetic
造血
  • 批准号:
    8181092
  • 财政年份:
    2010
  • 资助金额:
    $ 118.43万
  • 项目类别:
Regulatory T Cells in Allogeneic Transplantation
同种异体移植中的调节性 T 细胞
  • 批准号:
    7939868
  • 财政年份:
    2009
  • 资助金额:
    $ 118.43万
  • 项目类别:
NK Cells in GVHD and GVT
GVHD 和 GVT 中的 NK 细胞
  • 批准号:
    7673379
  • 财政年份:
    2008
  • 资助金额:
    $ 118.43万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 118.43万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 118.43万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 118.43万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 118.43万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 118.43万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 118.43万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 118.43万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 118.43万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 118.43万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 118.43万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了